Skip to main content

Table 2 Volume of treatment courses described in the literature for hospitalised patients

From: Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009

Treatment name Number of publications reporting use Total number of patients receiving treatment1 Median (IQR) number of patients receiving treatment per publication2 FDA drug approval status for use in influenza in 2009
Oseltamivir 154 31,737 63 (21–188) Approved for acute uncomplicated influenza, expanded under EUA April 2009
Zanamivir 54 368 2 (1–9) Approved for acute uncomplicated influenza, expanded under EUA April 2009
Peramivir 14 403 1 (1–3) Unapproved, eIND in April 2009, EUA October 2009
Amantadine 11 86 3 (1–13) Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated
Rimantadine 5 32 3 (1–13) Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated
Ribavirin 5 34 2 (1–6) Not approved for influenza
Intravenous immunoglobulin 4 44 4 (2–20) Not approved for influenza
Chinese medicines 3 1051 245 (56–750) Not approved for influenza
Convalescent Plasma 2 52 26 Not approved for influenza
Macrolides3 1 31 31 Not approved for influenza
Sirolimus 1 19 19 Not approved for influenza
Statins3 1 12 12 Not approved for influenza
  1. Volume of treatment courses described in the literature for hospitalised patients with 2009 H1N1 influenza during the pandemic period
  2. eIND emergency investigational new drug authorisation, EUA emergency use authorization
  3. 1Some patients received more than one treatment
  4. 2When publication describes use of that drug
  5. 3Where clear indication was influenza